Top

Clinical & Experimental Metastasis

Published in:

01-03-2004

Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients

Published in: Clinical & Experimental Metastasis | Issue 2/2004

Title: Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients
Publication date: 01-03-2004
Published in: Clinical & Experimental Metastasis / Issue 2/2004
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1023/B:CLIN.0000024739.43297.ba

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2004

Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: Role of cyclooxygenase-2

A small molecule antagonist of the α v β3 integrin suppresses MDA-MB-435 skeletal metastasis

Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications

Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247

Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance

Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer